Weber R J
Clinical Pharmacy Services, Shadyside Hospital, Pittsburgh, PA.
Clin Ther. 1993 Jan-Feb;15(1):180-91; discussion 168.
As new treatment options become available for patients with cancer or primary bone marrow failure, the additional economic burden that these treatments may place on the already stressed health care system raises concerns. Neutropenia is a major complication of these conditions and can add substantially to patient care costs. Granulocyte-macrophage colony-stimulating factor (GM-CSF), a cytokine that enhances neutrophil production and function, has recently been recommended as an effective treatment for neutropenia. Selected clinical studies suggest that GM-CSF can reduce the costs associated with the management of neutropenic patients by reducing the need for antibiotics and the duration of hospitalization. Treatment with GM-CSF also may be associated with an improved quality of life. Pharmacoeconomic and quality-of-life studies are required, however, to document these benefits. Based on currently available data, GM-CSF represents an economically and clinically appropriate treatment approach for neutropenia in patients who have undergone bone marrow transplantation or experience chemotherapy-induced neutropenia.
随着针对癌症患者或原发性骨髓衰竭患者的新治疗方案不断涌现，这些治疗可能给本就不堪重负的医疗保健系统带来的额外经济负担引发了人们的担忧。中性粒细胞减少是这些病症的主要并发症，会大幅增加患者的护理成本。粒细胞巨噬细胞集落刺激因子（GM-CSF）是一种可增强中性粒细胞生成和功能的细胞因子，最近已被推荐作为治疗中性粒细胞减少的有效方法。部分临床研究表明，GM-CSF可通过减少对抗生素的需求和缩短住院时间，降低与中性粒细胞减少患者管理相关的成本。GM-CSF治疗还可能与生活质量的改善相关。然而，需要开展药物经济学和生活质量研究来证明这些益处。基于现有数据，GM-CSF对于接受骨髓移植或经历化疗引起的中性粒细胞减少的患者而言，是一种经济且临床适用的中性粒细胞减少治疗方法。
